Protein / target
Inosine-5'-monophosphate dehydrogenase 2
Protein at a glance
Biological role
IMP dehydrogenase activity
Strongest disease association
acute lymphoblastic leukemia
Therapeutic maturity
Clinically validated target
Druggability
Small molecule
Clinical development
6 approved · 1 in clinical development
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function
Catalyzes the conversion of inosine 5'-phosphate (IMP) to xanthosine 5'-phosphate (XMP), the first committed and rate-limiting step in the de novo synthesis of guanine nucleotides, and therefore plays an important role in the regulation of cell growth (PubMed:7763314, PubMed:7903306). Could also have a single-stranded nucleic acid-binding activity and could play a role in RNA and/or DNA metabolism (PubMed:14766016). It may also have a role in the development of malignancy and the growth progression of some tumors
Subcellular location
Domains and Gene Ontology detail (20)Hide
Domains & features
Gene Ontology
- Ccytoplasm
- Ccytosol
- Cextracellular exosome
- Cextracellular region
- Cficolin-1-rich granule lumen
- Cmembrane
- Cnucleus
- Cperoxisomal membrane
- Csecretory granule lumen
- FDNA binding
- FIMP dehydrogenase activity
- Fmetal ion binding
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Metabolic enzyme activity
- ·IMP dehydrogenase activity
View underlying pathways (4)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Drugs targeting this protein
Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.
Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
Appears in clinical studies involving Crohn disease, immune system disorder, pulmonary sarcoidosis, graft versus host disease
ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.
Translational evidence
Why this target matters therapeutically — disease associations, drugs in development, tractability and safety, from Open Targets.
Highest-confidence therapeutic associations
Diseases where a drug acting on this target has already reached clinical development.
Highest overall evidence
Remaining associations by Open Targets' aggregated evidence score.
Show all associationsHide all associations
Open Targets ranks 335 associations for this target and we store the top 10 by aggregated score. The long tail is largely literature co-mention and RNA-expression evidence, not evidence that this target drives those diseases.
Known drugs · 7 total
pemphigus vulgaris · kidney transplant · chronic graft versus host disease
multiple sclerosis · kidney transplant · autoimmune disease
Crohn disease · immune system disorder · pulmonary sarcoidosis
acute myeloid leukemia by FAB classification · acute lymphoblastic leukemia · neoplasm
exocrine pancreatic carcinoma · hematopoietic and lymphoid cell neoplasm
lupus nephritis · nephrotic syndrome · rheumatoid arthritis
Tractability
Safety liabilities
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.
Show remaining trials (24)Hide
ClinicalTrials.gov via the drug-target graph.
Forefront confidence
Our own weighting of the evidence behind each disease association. Human genetics and clinical evidence count for most; literature co-mention counts for little, because two entities sharing an abstract is not evidence that one drives the other.
The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the underlying per-type scores are shown above so the calculation can be checked.
What's happening now
Recent activity around this target, drawn from one canonical event stream. Every item is reached through a drug that targets this protein, so each event is news about that drug rather than about the protein directly.
- Supplemental approval
Supplemental approval: MYCOPHENOLIC ACID (ANDA214376)
- Supplemental approval
Supplemental approval: MYCOPHENOLIC ACID (ANDA202555)
- Supplemental approval
Supplemental approval: MYCOPHENOLIC ACID (ANDA208315)
- Supplemental approval
Supplemental approval: MYCOPHENOLIC ACID (ANDA091558)
- Supplemental approval
Supplemental approval: MYCOPHENOLIC ACID (NDA050791)
- Supplemental approval
Supplemental approval: MYCOPHENOLIC ACID (ANDA211173)
- Supplemental approval
Supplemental approval: MYCOPHENOLIC ACID (ANDA217031)
- Supplemental approval
Supplemental approval: MYCOPHENOLIC ACID (ANDA216637)
- Supplemental approval
Supplemental approval: MYCOPHENILIC ACID (ANDA091248)
- Supplemental approval
Supplemental approval: MYCOPHENOLIC ACID (ANDA214630)
- Supplemental approval
Supplemental approval: MYCOPHENOLIC ACID (ANDA214289)
- Supplemental approval
Supplemental approval: MYCOPHENOLIC ACID (ANDA218603)
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.